Cubist wraps up $704M buy of antibiotics-maker

Cubist Pharmaceuticals has finalized its purchase of antibiotics-maker Trius Therapeutics for about $704 million. The deal will give Cubist access to Trius' tedizolid phosphate, a late-stage antibiotic under development for certain Gram-positive infections, as well as antibiotics programs that have yet to reach human studies.

View Full Article in:

Pharmaceutical Business Review Online · San Diego Union-Tribune

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA